StocktoriaAcurx Pharmaceuticals, Inc. ACXP
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$8.1M | -$14.1M | — | — | — |
| Net income | -$8.0M | -$14.1M | -$14.6M | -$12.1M | -$12.7M |
| Operating cash flow | -$6.8M | -$10.4M | -$9.8M | -$7.5M | -$5.0M |
| Total assets | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M |
| Total liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843,909 |
| Shareholders' equity | $5.3M | $615,121 | $4.7M | $7.3M | $12.4M |
| Ratios | |||||
| Return on assets | -103.6% | -365.6% | -189.1% | -129.0% | -96.2% |
| Return on equity | -151.2% | -2292.7% | -312.4% | -165.3% | -102.7% |
| Current ratio | — | 1.19 | 2.53 | 4.55 | 15.71 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001736243 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.